Earnings
Home›Earnings›Results›Gilead posts 10% revenue growth as HIV franchise expan…
Gilead posts 10% revenue growth as HIV franchise expands in Q2
HIV product sales rose 12% to $5.7 billion in Q2, and Yeztugo added $232 million, while HIV still drove nearly three-quarters of product sales.
Gilead Sciences reported strong fiscal second-quarter 2026 results, with total revenue up 10% year over year to approximately $7.8 billion, supported primarily by continued growth in its HIV franchise, including Biktarvy and the newly launched Yeztugo, according to Yahoo Finance.
In the quarter, Gilead’s HIV product sales rose 12% to $5.7 billion. The article attributes the growth mainly to higher average realized price and demand, with Descovy sales up 48% to $967 million and Biktarvy up 7% to $3.8 billion.
Yeztugo contributed $232 million in Q2, up from $15 million a year earlier, and the piece says its twice-yearly dosing could help expand Gilead’s prevention business. It also notes that it is still too early to determine Yeztugo’s long-term market share.
The article flags concentration risk, stating that HIV products generated nearly three-quarters of quarterly product sales, with HIV accounting for roughly $5.7 billion of about $7.6 billion total product sales. It also points to some diversification, saying the company’s liver disease portfolio sales rose 10% to $877 million in Q2, driven by demand for Livdelzi and other liver-related products.